Iridex Corporation Announces Publication of Study on Thermal Dynamics of Laser Treatments for Glaucoma

Iridex announces a study comparing thermal effects of two glaucoma laser treatments, highlighting efficiency and safety differences.

Quiver AI Summary

Iridex Corporation announced a new study published in Translational Vision Science & Technology, led by Dr. Tomas M. Grippo, that analyzes the thermal effects of transscleral laser treatments for glaucoma. The research utilizes a computer model to compare continuous wave transscleral cyclophotocoagulation (CW-TSCPC) with MicroPulse transscleral laser therapy (MicroPulse TLT), revealing that CW-TSCPC creates a larger area of intense tissue heating exceeding 100°C, while MicroPulse TLT results in a smaller, more uniform heat distribution that stays below this temperature. This study enhances the understanding and safety of these techniques, suggesting they could evolve to serve different roles in glaucoma treatment. Iridex CEO Patrick Mercer emphasized the importance of these findings in advancing innovation in glaucoma care. The study reflects Iridex's ongoing commitment to improving treatment options with its laser technologies.

Potential Positives

Iridex's publication in a peer-reviewed journal highlights its commitment to advancing scientific research and innovation in glaucoma treatment, enhancing the company's credibility within the medical community.
The study demonstrates that Iridex's MicroPulse technology provides a safer treatment option with reduced thermal damage compared to traditional methods, potentially improving patient outcomes.
The findings can lead to new clinical opportunities and applications for Iridex's products, strengthening its position in the ophthalmology market.
The CEO’s statement emphasizes the company's dedication to evidence-based innovation, which could attract further investment and enhance stakeholder confidence.

Potential Negatives

The study indicates that while both treatment techniques are effective, CW-TSCPC could potentially lead to more significant tissue damage due to higher temperatures, which may raise concerns about safety and long-term patient outcomes related to Iridex's treatment methodologies.
The emphasis on further optimization of both techniques suggests that current applications may not be fully optimized, potentially underscoring limitations in existing products and their performance in clinical settings.
The need for distinct but complementary roles for the two techniques may imply a competitive landscape where Iridex's MicroPulse TLT must consistently prove its value against other methodologies, increasing pressure on product differentiation and market share.

FAQ

What is the focus of the newly published Iridex study?

The study examines the thermal dynamics of transscleral laser treatments for glaucoma, comparing CW-TSCPC and MicroPulse TLT.

Who led the study on transscleral laser treatments?

The study was led by Dr. Tomas M. Grippo from the Grippo Glaucoma & Cataract Center in Buenos Aires, Argentina.

How do CW-TSCPC and MicroPulse TLT differ thermally?

CW-TSCPC produces a larger thermal zone exceeding 100°C, while MicroPulse TLT maintains lower temperatures and a smaller heated area.

What significance does this study have for glaucoma treatment?

The findings may help refine laser procedures, optimizing treatment safety and effectiveness for glaucoma management.

Where can I access the published study?

The article is available in the journal Translational Vision Science & Technology.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$IRIX Insider Trading Activity

$IRIX insiders have traded $IRIX stock on the open market 61 times in the past 6 months. Of those trades, 61 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $IRIX stock by insiders over the last 6 months:

WILLIAM M MOORE has made 6 purchases buying 112,024 shares for an estimated $111,054 and 0 sales.
ROMEO R DIZON (Chief Financial Officer) has made 54 purchases buying 53,655 shares for an estimated $57,949 and 0 sales.
PATRICK MERCER (President and CEO) purchased 250 shares for an estimated $240

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$IRIX Revenue

$IRIX had revenues of $12.5M in Q3 2025. This is an increase of 7.8% from the same period in the prior year.

You can track IRIX financials on Quiver Quantitative's IRIX stock page.

$IRIX Hedge Fund Activity

We have seen 11 institutional investors add shares of $IRIX stock to their portfolio, and 13 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

ARS INVESTMENT PARTNERS, LLC removed 110,060 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $97,061
CITADEL ADVISORS LLC added 78,302 shares (+251.2%) to their portfolio in Q3 2025, for an estimated $89,303
THOMPSON DAVIS & CO., INC. removed 56,726 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $64,696
GOLDMAN SACHS GROUP INC added 47,793 shares (+inf%) to their portfolio in Q3 2025, for an estimated $54,507
APEXIUM FINANCIAL, LP added 34,834 shares (+53.0%) to their portfolio in Q3 2025, for an estimated $39,728
CONCURRENT INVESTMENT ADVISORS, LLC removed 21,944 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $19,352
CENTIVA CAPITAL, LP added 18,768 shares (+inf%) to their portfolio in Q3 2025, for an estimated $21,404

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

Full Release

MOUNTAIN VIEW, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced a newly published study in Translational Vision Science & Technology (TVST) examining the thermal dynamics of transscleral laser treatments for glaucoma. ¹

Led by Tomas M. Grippo, MD, of the Grippo Glaucoma & Cataract Center (Buenos Aires, Argentina), the study provides the first quantitative computer model comparing the thermal tissue effects of continuous wave transscleral cyclophotocoagulation (CW-TSCPC) and transscleral laser therapy using MicroPulse ^® technology (MicroPulse TLT) with Iridex’s Cyclo G6 ^® Laser, G-Probe ^® and MicroPulse P3 ^® delivery devices.

Using advanced Monte Carlo computer simulations, the authors modeled how each technique heats the ciliary body and quantified temperature peaks, duration, and thermal spread. The modeling revealed that CW TSCPC produced a 2 mm-wide zone of tissue heating with temperatures exceeding 100°C for approximately 2.2 seconds. MicroPulse TLT generated a smaller 0.6-1.2 mm thermal zone and shorter duration peak temperatures, remaining below 100°C. Additionally, MicroPulse TLT showed a more uniform heat distribution than CW-TSCPC.

Dr. Grippo explained, “Our study uses a computational model to analyze heat behavior in the ciliary body during CW-TSCPC and MicroPulse TLT treatments. By linking these findings to the safety, effectiveness, and mechanisms of action described in the literature for both treatments, we can reinterpret existing clinical evidence from a fresh perspective. This approach strengthens our understanding and conceptual framework for these techniques and provides insights that may help refine both laser procedures for improved patient outcomes.”

The authors concluded that both techniques share a thermal continuum, and with further optimization, each may evolve to serve distinct but complementary roles from refractory glaucoma to earlier intervention cases.

“Dr. Grippo’s work underscores Iridex’s commitment to advancing evidence-based innovation in glaucoma care,” said Patrick Mercer, CEO of Iridex Corporation. “By deepening our scientific understanding of how these two transscleral laser approaches interact with ocular tissues, we can continue to improve treatment optimization and safety creating broad clinical opportunities for both CW-TSCPC and MicroPulse TLT in modern glaucoma management.”

The article is available in Translational Vision Science & Technology .

About Iridex Corporation
Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, which include capital equipment and consumable probes for the ophthalmology market. The Company’s proprietary MicroPulse ^® technology delivers the therapeutic benefits of laser treatment while minimizing tissue damage, offering a safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at www.iridex.com .

Investor Relations Contact
Philip Taylor
Gilmartin Group
[email protected]

Media Contact
Joan Stauffer
[email protected]

For more information about Iridex technologies, visit www.iridex.com .

References

Grippo TM, LaMarche K, Davreux AM, Stauffer J, Stacey S, Arnold K. Thermal tissue modeling of the ciliary body with continuous wave transscleral cyclophotocoagulation and transscleral laser therapy using micropulse technology . Transl Vis Sci Technol . 2025;14(11):32.